Literature DB >> 8157964

An isotype switched and somatically mutated rheumatoid factor clone isolated from a MRL-lpr/lpr mouse exhibits limited intraclonal affinity maturation.

B A Jacobson1, J Sharon, H Shan, M Shlomchik, M G Weigert, A Marshak-Rothstein.   

Abstract

Employing site-directed mutagenesis we have reconstructed and expressed the germ-line precursor of an expanded rheumatoid factor (RF) clone. This RF clone, designated clone F, was isolated from an autoimmune MRL/MpJ-lpr/lpr mouse. Most of the clone members were extensively mutated and isotyped-switched. The predominant isotype of clone F was gamma 3. The RF bound specifically to the MRL gamma 2 a allotype (Igh-1j) but not to the B6 gamma 2a allotype (Igh-1b). The germ-line antibody was also found to bind gamma 2a in an RF assay. The affinities of the germ-line RF and representative members of the clone were measured in an ELISA-based equilibrium binding assay. The dissociation constant (Kd) of the germ-line RF was 2.5 x 10(-6) M. All of the expressed clone members had affinities within a two- to sixfold range of the germ line, indicating that the mechanisms of somatic hypermutation and selection resulted in only limited affinity maturation of this autoantibody clone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157964

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Isotype-dependent pathogenicity of autoantibodies: analysis in experimental autoimmune hemolytic anemia.

Authors:  S Izui; L Fossati-Jimack; S A da Silveira; T Moll
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors.

Authors:  Sean R Christensen; Mark J Shlomchik
Journal:  Semin Immunol       Date:  2007-02-02       Impact factor: 11.130

3.  FcγRIIB regulation of BCR/TLR-dependent autoreactive B-cell responses.

Authors:  Ana M Avalos; Melissa B Uccellini; Petar Lenert; Gregory A Viglianti; Ann Marshak-Rothstein
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

4.  Control of autoantibody affinity by selection against amino acid replacements in the complementarity-determining regions.

Authors:  M Børretzen; I Randen; E Zdárský; O Førre; J B Natvig; K M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

5.  Expression of the B cell repertoire in lpr mice; abnormal expansion of a few VHJ558 germ-line genes.

Authors:  M E Alarcón-Riquelme; C Fernández
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

6.  High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia.

Authors:  L Fossati-Jimack; L Reininger; Y Chicheportiche; R Clynes; J V Ravetch; T Honjo; S Izui
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

7.  Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination.

Authors:  Fiona Tea; Joseph A Lopez; Sudarshini Ramanathan; Vera Merheb; Fiona X Z Lee; Alicia Zou; Deepti Pilli; Ellis Patrick; Anneke van der Walt; Mastura Monif; Esther M Tantsis; Eppie M Yiu; Steve Vucic; Andrew P D Henderson; Anthony Fok; Clare L Fraser; Jeanette Lechner-Scott; Stephen W Reddel; Simon Broadley; Michael H Barnett; David A Brown; Jan D Lunemann; Russell C Dale; Fabienne Brilot
Journal:  Acta Neuropathol Commun       Date:  2019-09-03       Impact factor: 7.801

Review 8.  Toll-like receptors in systemic autoimmune disease.

Authors:  Ann Marshak-Rothstein
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

9.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.